hiv antigens

Summary

Summary: Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens.

Top Publications

  1. ncbi Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants
    Will Fischer
    Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
    Nat Med 13:100-6. 2007
  2. pmc HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
    M Juliana McElrath
    Vaccine and Infectious Disease Institute and the HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Lancet 372:1894-905. 2008
  3. pmc Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
    Susan P Buchbinder
    HIV Research Section, San Francisco Department of Public Health, San Francisco, CA, USA
    Lancet 372:1881-93. 2008
  4. ncbi Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope
    Astrid K N Iversen
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9AD, UK
    Nat Immunol 7:179-89. 2006
  5. pmc Cost-effective production of a vaginal protein microbicide to prevent HIV transmission
    Koreen Ramessar
    Departament de Produccio Vegetal i Ciencia Forestal, Universitat de Lleida, Avenida Alcalde Rovira Roure, 191, Lleida, 25198, Spain
    Proc Natl Acad Sci U S A 105:3727-32. 2008
  6. pmc Dynamics of immune escape during HIV/SIV infection
    Christian L Althaus
    Theoretical Biology, Utrecht University, The Netherlands
    PLoS Comput Biol 4:e1000103. 2008
  7. pmc HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach
    Qiana L Matthews
    Division of Human Gene Therapy, Departments of Medicine, Pathology, Surgery, Obstetrics and Gynecology, and the Gene Therapy Center, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
    PLoS ONE 5:e11815. 2010
  8. ncbi HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus
    Marcus Altfeld
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, Massachusetts 02129, USA
    Nature 420:434-9. 2002
  9. ncbi Characterization of an HLA-C-restricted CTL response in chronic HIV infection
    Azure T Makadzange
    Medical Research Council, Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Eur J Immunol 40:1036-41. 2010
  10. ncbi Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses
    F Simon
    Laboratoire de Virologie and Centre de Primatologie, , Franceville, Gabon
    AIDS Res Hum Retroviruses 17:937-52. 2001

Detail Information

Publications205 found, 100 shown here

  1. ncbi Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants
    Will Fischer
    Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
    Nat Med 13:100-6. 2007
    ..Mosaics provide diversity coverage comparable to that afforded by thousands of separate peptides, but, because the fragments of natural proteins are compressed into a small number of native-like proteins, they are tractable for vaccines...
  2. pmc HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis
    M Juliana McElrath
    Vaccine and Infectious Disease Institute and the HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Lancet 372:1894-905. 2008
    ..We assessed vaccine-induced immunity and its potential contributions to infection risk...
  3. pmc Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial
    Susan P Buchbinder
    HIV Research Section, San Francisco Department of Public Health, San Francisco, CA, USA
    Lancet 372:1881-93. 2008
    ..The Step Study directly assessed the efficacy of a cell-mediated immunity vaccine to protect against HIV-1 infection or change in early plasma HIV-1 levels...
  4. ncbi Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope
    Astrid K N Iversen
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9AD, UK
    Nat Immunol 7:179-89. 2006
    ..Thus, viral escape from CTL responses does not necessarily correlate with disease progression...
  5. pmc Cost-effective production of a vaginal protein microbicide to prevent HIV transmission
    Koreen Ramessar
    Departament de Produccio Vegetal i Ciencia Forestal, Universitat de Lleida, Avenida Alcalde Rovira Roure, 191, Lleida, 25198, Spain
    Proc Natl Acad Sci U S A 105:3727-32. 2008
    ..We conclude that this protein production system may provide a means to achieve microbicide ingredient manufacture at costs that would allow product introduction and manufacture in the developing world...
  6. pmc Dynamics of immune escape during HIV/SIV infection
    Christian L Althaus
    Theoretical Biology, Utrecht University, The Netherlands
    PLoS Comput Biol 4:e1000103. 2008
    ....
  7. pmc HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach
    Qiana L Matthews
    Division of Human Gene Therapy, Departments of Medicine, Pathology, Surgery, Obstetrics and Gynecology, and the Gene Therapy Center, University of Alabama at Birmingham, Birmingham, Alabama, United States of America
    PLoS ONE 5:e11815. 2010
    ..Our study herein focuses on generation of multivalent vaccine vectors presenting HIV antigens within the Ad capsid protein hexon, as well as expressing an HIV antigen as a transgene...
  8. ncbi HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus
    Marcus Altfeld
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, Massachusetts 02129, USA
    Nature 420:434-9. 2002
    ..The lack of cross-protective immunity for closely related HIV-1 strains, despite persistent recognition of multiple CD8 epitopes, has important implications for public health and vaccine development...
  9. ncbi Characterization of an HLA-C-restricted CTL response in chronic HIV infection
    Azure T Makadzange
    Medical Research Council, Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
    Eur J Immunol 40:1036-41. 2010
    ..HLA-C-restricted CTL in chronic HIV infection are memory cells of an intermediate phenotype, characterized by high CD27 and low CD28 expression and lack of perforin production...
  10. ncbi Synthetic peptide strategy for the detection of and discrimination among highly divergent primate lentiviruses
    F Simon
    Laboratoire de Virologie and Centre de Primatologie, , Franceville, Gabon
    AIDS Res Hum Retroviruses 17:937-52. 2001
    ..This method should prove useful for studies of lentivirus prevalence and diversity in human and nonhuman primates, and may also have the potential to detect previously undescribed SIVs...
  11. pmc Efficient processing of the immunodominant, HLA-A*0201-restricted human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking sequences
    C Brander
    AIDS Research Center and Infectious Disease Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Virol 73:10191-8. 1999
    ..These data suggest that escape from this immunodominant CTL response is not frequently accomplished by changes in the epitope flanking sequences...
  12. ncbi Pairwise decomposition of residue interaction energies of single chain Fv with HIV-1 p17 epitope variants
    Vannajan Sanghiran Lee
    Computational Simulation and Modeling Laboratory CSML, Department of Chemistry and Center for Innovation in Chemistry, Chiang Mai University, Chiang Mai, 50200, Thailand
    Mol Immunol 47:982-90. 2010
    ..00 kcal/mol in comparison to the original substrate...
  13. ncbi Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele
    Guido Ferrari
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Immunol 173:2126-33. 2004
    ....
  14. pmc Entropic switch regulates myristate exposure in the HIV-1 matrix protein
    Chun Tang
    Howard Hughes Medical Institute and Department of Chemistry and Biochemistry, University of Maryland Baltimore County, 1000 Hilltop Circle, Baltimore, MD 21250 5398, USA
    Proc Natl Acad Sci U S A 101:517-22. 2004
    ..Our findings indicate that the HIV-1 myristyl switch is regulated not by mechanically induced conformational changes, as observed for other myristyl switches, but instead by entropic modulation of a preexisting equilibrium...
  15. ncbi Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy
    Lucy Dorrell
    MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK
    Vaccine 25:3277-83. 2007
    ..These data confirm the safety of MVA.HIVA in HIV-1-infected individuals and provide support for further evaluation of MVA-vectored vaccines in prophylactic and therapeutic immunisation strategies...
  16. pmc Adaptation of HIV-1 to human leukocyte antigen class I
    Yuka Kawashima
    Division of Viral Immunology, Center for AIDS Research, Kumamoto University, 2 2 1 Honjo, Kumamoto 860 0811, Japan
    Nature 458:641-5. 2009
    ....
  17. ncbi Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation
    Fusheng Li
    Statistical Center for HIV Aids Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Vaccine 24:6893-904. 2006
    ..The usability of PTE peptide set was manifested by detection of Nef-specific CTL responses in HIV-1 subtype B infections...
  18. pmc Consistent cytotoxic-T-lymphocyte targeting of immunodominant regions in human immunodeficiency virus across multiple ethnicities
    Nicole Frahm
    Partners AIDS Research Center, Endocrine Unit, Massachusetts General Hospital, Charlestown, Massachusetts 02129 2000, USA
    J Virol 78:2187-200. 2004
    ..The present study thus identifies factors that contribute to the immunogenicity of these highly targeted and relatively conserved sequences in HIV that may represent promising vaccine candidates for ethnically heterogeneous populations...
  19. pmc Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions
    Juan García-Arriaza
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, Consejo Superior de Investigaciones Cientificas CSIC, Madrid, Spain
    PLoS ONE 5:e12395. 2010
    ....
  20. ncbi MHC-I-restricted presentation of HIV-1 virion antigens without viral replication
    F Buseyne
    Laboratoire d'Immunopathologie Viralem, Institut Pasteur, Paris, France
    Nat Med 7:344-9. 2001
    ..These results provide new insights into how anti-HIV cytotoxic T lymphocytes can be activated and have implications for anti-HIV vaccine design...
  21. ncbi HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry
    Catherine A Blish
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    AIDS 21:693-702. 2007
    ..An effective HIV-1 vaccine or microbicide must block the transmitted virus variants that initially establish a new infection; consequently, it is critical that such viruses be isolated and characterized...
  22. ncbi Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance
    Stefan Tenzer
    Institute of Immunology, University of Mainz, Mainz, Germany
    Nat Immunol 10:636-46. 2009
    ..Our analyses show that antigen processing shapes CTL response hierarchies and that viral evolution modifies cleavage patterns and suggest strategies for in vitro vaccine optimization...
  23. ncbi Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART)
    C M Gray
    Center for AIDS Research, Division of Infectious Diseases and Geographic Medicine, Stanford University Medical Center, Stanford, CA 94305
    J Immunol 162:1780-8. 1999
    ..In conclusion, this study provides evidence that persistently replicating viral populations are probably required to maintain high frequencies of HIV-1 epitope-specific CD8+ T cells in asymptomatic chronically infected individuals..
  24. ncbi Fc receptor but not complement binding is important in antibody protection against HIV
    Ann J Hessell
    Department of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    Nature 449:101-4. 2007
    ..Overall, the data suggest the potential importance of activity against both infected cells and free virus for effective protection against HIV...
  25. pmc Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative
    Barbara Muller
    Abteilung Virologie, Universitätklinikum Heidelberg, Germany
    J Virol 78:10803-13. 2004
    ..The fluorescent virus derivative is a useful tool for investigating the interaction of HIV with live cells...
  26. pmc Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV-suppressive activity
    Jorge R Almeida
    Institut National de la Santé et de la Recherche Médicale Unité, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, Paris, France
    Blood 113:6351-60. 2009
    ....
  27. pmc HLA-B57-restricted cytotoxic T-lymphocyte activity in a single infected subject toward two optimal epitopes, one of which is entirely contained within the other
    P J Goulder
    Partners AIDS Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    J Virol 74:5291-9. 2000
    ..In addition, these studies demonstrate marked differences in the length of peptides presented by HLA-B57, an allele which is associated with nonprogressive human immunodeficiency virus infection...
  28. ncbi Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH
    Simona Fiorentini
    Department of Experimental and Applied Medicine, University of Brescia Medical School, Brescia, Italy
    Biopolymers 76:334-43. 2004
    ..Preclinical immunogenicity data for AT20-KLH provide the basis for evaluation of the peptide-based vaccine, alone and in combination with p17 or p17 DNA vaccines, in Phase I clinical trials...
  29. pmc Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells
    Cinzia Giagulli
    Department of Experimental and Applied Medicine, University of Brescia, Brescia, Italy
    PLoS ONE 6:e17831. 2011
    ..Moreover, it provides the first evidence on the presence of a p17 natural variant mimicking the p17Δ36-induced signalling in B cells and displaying the capacity of promoting B cell growth and tumorigenesis...
  30. ncbi Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual
    T Harrer
    Department of Medicine III with Institute of Clinical Immunology, University of Erlangen Nuremberg, Erlangen, Germany
    J Immunol 161:4875-81. 1998
    ..In addition, they demonstrate that Ag processing can allow for presentation of overlapping epitopes in the same infected cell, which can be affected quite differently by sequence variation...
  31. ncbi Antagonism of cytotoxic T lymphocyte-mediated lysis by natural HIV-1 altered peptide ligands requires simultaneous presentation of agonist and antagonist peptides
    A K Sewell
    Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, GB
    Eur J Immunol 27:2323-9. 1997
    ..We found no evidence that CTL exposed to an antagonist received a functionally negative signal since these CTL retained an unimpaired capacity to lyse targets bearing wild-type peptide...
  32. pmc The antiviral efficacy of HIV-specific CD8⁺ T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate
    Srinika R F Ranasinghe
    Medical Research Council Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom
    PLoS Pathog 7:e1001341. 2011
    ..This has important implications for future vaccine design strategies since efficient presentation of conserved viral epitopes is necessary to promote enhanced anti-viral immune responses...
  33. ncbi The rationale behind a vaccine based on multiple HIV antigens
    E Rollman
    Swedish Institute for Infectious Disease Control, Solna, Sweden
    Microbes Infect 7:1414-23. 2005
    ..This article describes pre-clinical and clinical work preceding the initiation of clinical HIV-1 phase I/II trials...
  34. pmc HIV-1 p17 matrix protein interacts with heparan sulfate side chain of CD44v3, syndecan-2, and syndecan-4 proteoglycans expressed on human activated CD4+ T cells affecting tumor necrosis factor alpha and interleukin 2 production
    Maria A De Francesco
    Institute of Microbiology, University of Brescia Medical School, Brescia, Italy
    J Biol Chem 286:19541-8. 2011
    ..Moreover, we observed a stimulatory or inhibitory activity when CD4(+) T cells were activated with mitogens together with nanomolar or micromolar concentrations of the matrix protein...
  35. pmc Reappearance of founder virus sequence in human immunodeficiency virus type 1-infected patients
    A C Karlsson
    Divisions of Clinical Virology, Department of Immunology, Microbiology, Pathology and Infectious Diseases, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden
    J Virol 73:6191-6. 1999
    ..In samples from three patients, a rapid replacement of the major sequence occurred but the original sequence reappeared later simultaneously with clinical deterioration and increased plasma viral load...
  36. ncbi Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17
    Simona Fiorentini
    Section of Microbiology, Department of Experimental and Applied Medicine, University of Brescia, p le Spedali Civili 1, I 25123 Brescia, Italy
    Vaccine 26:4758-65. 2008
    ..This finding shows that AT20, as an immunogenic molecule, elicits broadly neutralizing anti-p17 antibodies...
  37. pmc Impaired processing and presentation of cytotoxic-T-lymphocyte (CTL) epitopes are major escape mechanisms from CTL immune pressure in human immunodeficiency virus type 1 infection
    Yoshiyuki Yokomaku
    AIDS Research Center, National Institute of Infectious Diseases, University of Tokyo, Tokyo, Japan
    J Virol 78:1324-32. 2004
    ..We emphasize the importance of testing HIV-1 variants in an endogenous expression system...
  38. pmc Antibody polyspecificity and neutralization of HIV-1: a hypothesis
    Barton F Haynes
    Duke Human Vaccine Institute, Duke University School of Medicine, Durham NC 27710, USA
    Hum Antibodies 14:59-67. 2005
    ....
  39. ncbi Diversity considerations in HIV-1 vaccine selection
    Brian Gaschen
    Los Alamos National Laboratory, Los Alamos, NM 87545, USA
    Science 296:2354-60. 2002
    ..Consensus or ancestor sequences could be used in vaccine design to minimize the genetic differences between vaccine strains and contemporary isolates, effectively reducing the extent of diversity by half...
  40. pmc Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates
    Petra Mooij
    Department of Virology, Biomedical Primate Research Centre BPRC, P O Box 3306, 2280 GH Rijswijk, The Netherlands
    J Virol 82:2975-88. 2008
    ..In contrast, in this setting, animals with strong vaccine-induced polyfunctional CD4(+) T-cell responses showed efficacies similar to those with stronger CD8(+) T-cell responses...
  41. ncbi Use of viral vectors for the development of vaccines
    Matthias Liniger
    Berna Biotech Ltd, Bern, Switzerland
    Expert Rev Vaccines 6:255-66. 2007
    ..Most notably, novel vaccines based on live, recombinant vectors may combine the induction of broad, strong and persistent immune responses with acceptable safety profiles...
  42. ncbi Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens
    Carmen E Gomez
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, Ciudad Universitaria Cantoblanco, 28049 Madrid, Spain
    Vaccine 27:3165-74. 2009
    ..analyzed the ability of a soluble form of hexameric CD40L (sCD40L) to stimulate specific immune responses to HIV antigens when inoculated in mice during priming with DNA and in the booster with MVA or NYVAC, expressing the vectors ..
  43. ncbi HIV antigens can induce TGF-beta(1)-producing immunoregulatory CD8+ T cells
    Mohammed L Garba
    Department of Microbiology and Immunology, University of North Carolina, Chapel Hill NC 27599, USA
    J Immunol 168:2247-54. 2002
    ..This represents an important mechanism by which an HIV-specific response can nonspecifically suppress both HIV-specific and unrelated immune responses...
  44. pmc Substantial differences in specificity of HIV-specific cytotoxic T cells in acute and chronic HIV infection
    P J Goulder
    Partners AIDS Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts 02129, USA
    J Exp Med 193:181-94. 2001
    ..This finding is an important consideration in vaccine design and in the evaluation of vaccine candidates...
  45. ncbi Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure
    Richard Strasser
    Institute of Applied Genetics and Cell Biology, University of Natural Resources and Applied Life Sciences, Muthgasse 18, 1190 Vienna, Austria
    Plant Biotechnol J 6:392-402. 2008
    ..The generated RNAi lines were stable, viable and did not show any obvious phenotype, thus providing a robust tool for the production of therapeutically relevant glycoproteins in plants with a humanized N-glycan structure...
  46. ncbi Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity
    Lindvi Gudmundsdotter
    Karolinska Institutet and Swedish Institute for Infectious Disease Control, Stockholm, Sweden
    Vaccine 27:4468-74. 2009
    ..Our results suggest that vaccinia-based vectors can be used to efficiently induce immune responses to vectored HIV-1 antigens, even in individuals with pre-existing immunity to vaccinia virus...
  47. ncbi DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation
    Arnaud Moris
    Groupe Virus et Immunité, URA CNRS 1930, Institut Pasteur, Paris, France
    Blood 103:2648-54. 2004
    ..Altogether, our results highlight new aspects of DC-SIGN interactions with HIV-1. The lectin does not significantly protect captured virions against degradation and promotes MHC-I exogenous presentation of HIV-1 antigens...
  48. pmc Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteins
    José Maria Marcelino
    Unidade de Retrovirus e Infecçôes Associadas, Centro de Patogenese Molecular, Faculdade de Farmácia de Lisboa, Avenida das Forças Armadas, 1649 019 Lisboa, Portugal
    J Clin Microbiol 44:607-11. 2006
    ..Both polypeptides showed 100% specificity. Clinical sensitivity was 100% for rgp36 and 93.4% for rpC2-C3. ELISA-HIV2 may be used for the specific diagnosis and confirmation of HIV-2 infection...
  49. pmc Differential membrane binding of the human immunodeficiency virus type 1 matrix protein
    W Zhou
    Cell Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Virol 70:8540-8. 1996
    ..It is likely that such a conformational change results in an N-terminal myristyl switch which governs differential membrane binding...
  50. ncbi HIV-1 matrix protein p17 enhances the proliferative activity of natural killer cells and increases their ability to secrete proinflammatory cytokines
    Marco Vitale
    Department of Anatomy, Pharmacology and Forensic Medicine, Ospedale Maggiore, University of Parma, Italy
    Br J Haematol 120:337-43. 2003
    ..The property of p17 to increase the production of TNF-alpha and IFN-gamma might be a mechanism used by HIV-1 to modulate the immune system to support its replication and spreading...
  51. pmc Dendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals
    Nuria Climent
    Service of Immunology, Hospital Clinic de Barcelona, Barcelona, Spain
    PLoS ONE 6:e19644. 2011
    ..These results evidence the adjuvant role of the vector itself (MVA) and support the clinical development of prophylactic and therapeutic anti-HIV vaccines based on MVA-B...
  52. pmc Preferential infection shortens the life span of human immunodeficiency virus-specific CD4+ T cells in vivo
    Jason M Brenchley
    Human Virology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA
    J Virol 80:6801-9. 2006
    ....
  53. pmc The HIV/AIDS vaccine candidate MVA-B administered as a single immunogen in humans triggers robust, polyfunctional, and selective effector memory T cell responses to HIV-1 antigens
    Carmen Elena Gómez
    Centro Nacional de Biotecnologia, CSIC, Madrid 28049, Spain
    J Virol 85:11468-78. 2011
    ..Thus, on the basis of the immune profile of MVA-B in humans, this immunogen can be considered a promising HIV/AIDS vaccine candidate...
  54. pmc Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy
    J P Casazza
    Department of Internal Medicine, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390-9113, USA
    J Virol 75:6508-16. 2001
    ....
  55. ncbi HIV p17 enhances lymphocyte proliferation and HIV-1 replication after binding to a human serum factor
    M A De Francesco
    Institute of Microbiology, Brescia University Medical School, Italy
    AIDS 12:245-52. 1998
    ..To analyse the role of recombinant HIV-1 protein p17 in the modulation of cell activity...
  56. pmc Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation
    L Buonaguro
    Laboratory of Viral Oncology and AIDS Reference Center, Istituto Nazionale Tumori Fond G Pascale, Via Mariano Semmola, 1, 80131 Naples, Italy
    J Virol 79:7059-67. 2005
    ....
  57. pmc Portable flanking sequences modulate CTL epitope processing
    Sylvie Le Gall
    Partners AIDS Research Center and Howard Hughes Medical Institute, Massachusetts General Hospital MGH, Harvard Medical School, Boston, Massachusetts 02129, USA
    J Clin Invest 117:3563-75. 2007
    ..Such portable epitope processing determinants provide what we believe is a novel approach to optimizing CTL responses elicited by vaccine vectors...
  58. ncbi HIV type 1 vaccines for worldwide use: predicting in-clade and cross-clade breadth of immune responses
    Adam C Finnefrock
    Vaccine and Biologics Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    AIDS Res Hum Retroviruses 23:1283-92. 2007
    ..For more diverse proteins, adding a second strain can add a significant increase in breadth, although for three or more strains the intrinsic diversity of the protein leads to diminishing improvement...
  59. pmc Identification of cryptic MHC I-restricted epitopes encoded by HIV-1 alternative reading frames
    Sylvain Cardinaud
    Unité Cellulaire Antivirale, Institut Pasteur, 28 rue du Dr Roux, 75724 Paris Cedex 15, France
    J Exp Med 199:1053-63. 2004
    ..This should be taken into account when designing vaccine strategies aimed at activating these responses...
  60. ncbi Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses
    Matthias Liniger
    Crucell Berna Biotech LTD, Rehhagstrasse 79, 3018 Bern, Switzerland
    Vaccine 27:3299-305. 2009
    ..by different regimens and formulations showed potent humoral and cellular immune responses against MV and HIV antigens. Recombinant MV-HIV expressing Gag protein conferred protective immunity in tg-mice after a high-dose ..
  61. pmc Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens
    José Luis Nájera
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Ciudad Universitaria Cantoblanco, Madrid, Spain
    PLoS ONE 5:e11406. 2010
    ..We have previously described that the presence of C7L in the NYVAC genome prevents the induction of apoptosis and renders the vector capable of replication in human and murine cell lines while maintaining an attenuated phenotype in mice...
  62. pmc Sublingual administration of an adenovirus serotype 5 (Ad5)-based vaccine confirms Toll-like receptor agonist activity in the oral cavity and elicits improved mucosal and systemic cell-mediated responses against HIV antigens despite preexisting Ad5 immuni
    Daniel M Appledorn
    Department of Microbiology and Molecular Genetics, College of Osteopathic Medicine, Michigan State University, East Lansing, MI 48824, USA
    Clin Vaccine Immunol 18:150-60. 2011
    ..vaccination regimen coupled with augmentation of TLR-dependent pathways active in the oral cavity makes s.l. delivery a promising method for HIV vaccine development specifically, as well as for many other vaccine applications in general...
  63. ncbi Activation of HIV-1 specific CD4 and CD8 T cells by human dendritic cells: roles for cross-presentation and non-infectious HIV-1 virus
    Marie Larsson
    The Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York 10021, USA
    AIDS 16:1319-29. 2002
    ..Despite this, anti-HIV responses are generated that control viremia following acute infection...
  64. ncbi Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C
    Carmen Elena Gómez
    Department of Molecular and Cellular Biology, Centro Nacional de Biotecnologia, CSIC, Ciudad Universitaria Cantoblanco, 28049 Madrid, Spain
    Vaccine 25:1969-92. 2007
    ..These results demonstrate the immunogenic potential of MVA-C and NYVAC-C as novel vaccine candidates against clade C of HIV-1...
  65. ncbi HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS
    Simona Fiorentini
    Section of Microbiology, Department of Experimental and Applied Medicine, University of Brescia, 25123 Brescia, Italy
    Pharmacol Ther 128:433-44. 2010
    ....
  66. ncbi Increased detection of HIV-specific T cell responses by combination of central sequences with comparable immunogenicity
    Nicole Frahm
    Partners AIDS Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02129 2000, USA
    AIDS 22:447-56. 2008
    ..To evaluate the recognition of computationally designed, centralized HIV-1 antigens derived from clade B, C and group M sequences by individuals infected with HIV-1-M clades B and C...
  67. pmc Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals
    Qin Lizeng
    Research Center, South Hospital, Stockholm, Sweden
    J Virol 78:7016-22. 2004
    ..05). Thus, we describe HIV-2-specific serum IgA antigen reactivity and show a more potent serum IgA-mediated HIV-2-neutralizing activity in EGSN individuals than in HIV-2-infected patients...
  68. pmc Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection
    D A Price
    Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Proc Natl Acad Sci U S A 94:1890-5. 1997
    ..Other proviruses had mutations that abolished the Nef epitope altogether. These results provide clear evidence that CTLs exert selection pressure on the viral population in acute HIV-1 infection...
  69. pmc Oxadiazols: a new class of rationally designed anti-human immunodeficiency virus compounds targeting the nuclear localization signal of the viral matrix protein
    Omar Haffar
    International Therapeutics Inc, Seattle, Washington, USA
    J Virol 79:13028-36. 2005
    ..Compounds inhibiting HIV-1 nuclear import may be attractive candidates for further development...
  70. ncbi Dendritic cells and HIV-specific CD4+ T cells: HIV antigen presentation, T-cell activation, and viral transfer
    Arnaud Moris
    Groupe Virus et Immunité, Unité de Recherche Associée URA Centre National de la Recherche Scientifique CNRS 1930, Paris, France
    Blood 108:1643-51. 2006
    ..molecule 3-grabbing nonintegrin (DC-SIGN/CD209), which internalizes virions, promoted MHC-II presentation of HIV antigens. Activation of HS cells by HIV-exposed DCs triggered an efficient viral spread in lymphocytes...
  71. pmc Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD4+ T lymphocytes
    Concepcion Marañon
    Departement d Immunologie, Institut Cochin, Institut National de la Sante et de la Recherche Medicale U567, Unite Mixte de Recherche, Centre National de la Recherche Scientifique 8104, Institut Federatif de Recherche 116, Universite Paris V, Paris, France
    Proc Natl Acad Sci U S A 101:6092-7. 2004
    ....
  72. pmc Conflicting selection pressures on T-cell epitopes in HIV-1 subtype B
    Stephanie Jiménez Irausquin
    Department of Biological Sciences, University of South Carolina, Coker Life Sciences Building, 700 Sumter St, Columbia, SC 29208, USA
    Infect Genet Evol 11:483-8. 2011
    ....
  73. ncbi A novel simian immunodeficiency virus isolated from a Schmidt's guenon (Cercopithecus ascanius schmidti)
    Ernst J Verschoor
    Department of Virology, Biomedical Primate Research Centre, PO Box 3306, 2206 GH Rijswijk, The Netherlands
    J Gen Virol 85:21-4. 2004
    ..Phylogenetic analysis showed that this virus, designated SIVschm, shares a distant relationship with SIVgsn, isolated from greater spot-nosed monkeys, and is one of the most divergent SIVs identified to date...
  74. ncbi Exploiting the defensive sugars of HIV-1 for drug and vaccine design
    Christopher N Scanlan
    Glycobiology Institute, Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK
    Nature 446:1038-45. 2007
    ..Intriguingly, however, recent findings suggest that these carbohydrates, which have evolved to protect HIV and promote its transmission, are also attractive therapeutic targets...
  75. ncbi Advantageous features of plant-based systems for the development of HIV vaccines
    Michael E Horn
    ProdiGene, College Station, TX 77845, USA
    J Drug Target 11:539-45. 2003
    ..Expression levels were achieved that are compatible with conducting oral delivery trials in animals...
  76. ncbi Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference
    Natasha Larke
    Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    Eur J Immunol 37:566-77. 2007
    ..Thus, these results have important ramifications for the design of both prophylactic and therapeutic vaccines against HIV-1 and other highly variable pathogens...
  77. ncbi Rapid qualitative and quantitative analysis of T-cell responses in HIV-1-infected individuals receiving successful HAART and HIV-1 sero-negative controls: concomitant assessment of perforin, IFN-gamma and IL-4 secretion
    Catherine T Burton
    Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    J Immunol Methods 308:216-30. 2006
    ....
  78. pmc Sequential broadening of CTL responses in early HIV-1 infection is associated with viral escape
    Annika C Karlsson
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, California, United States of America
    PLoS ONE 2:e225. 2007
    ....
  79. pmc Human Polycomb group EED protein negatively affects HIV-1 assembly and release
    Dina Rakotobe
    Laboratoire de Virologie and Pathologie Humaine, Université Lyon I and CNRS FRE 3011, Faculte de Medecine Laennec, Lyon Cedex 08, France
    Retrovirology 4:37. 2007
    ..The aim of the present study was to analyze the possible biological role of EED in HIV-1 replication, using the HIV-1-based vector HIV-Luc and EED protein expressed by DNA transfection of 293T cells...
  80. ncbi High-level expression of human immunodeficiency virus antigens from the tobacco and tomato plastid genomes
    Fei Zhou
    Max Planck Institut fur Molekulare Pflanzenphysiologie, Am Muhlenberg 1, D 14476 Potsdam Golm, Germany
    Plant Biotechnol J 6:897-913. 2008
    ..It is shown that the HIV antigens p24 (the major target of T-cell-mediated immune responses in HIV-positive individuals) and Nef can be expressed ..
  81. pmc Magnitude and frequency of cytotoxic T-lymphocyte responses: identification of immunodominant regions of human immunodeficiency virus type 1 subtype C
    V Novitsky
    Department of Immunology and Infectious Diseases, Harvard School of Public Health, FXB 402, 651 Huntington Avenue, Boston, MA 02115, USA
    J Virol 76:10155-68. 2002
    ..Furthermore, the analysis of HIV-1C-specific immune responses on a population level represents a comprehensive systematic approach in HIV vaccine design and should be considered for other HIV-1 subtypes and/or different geographic areas...
  82. pmc Expression of HIV-1 antigens in plants as potential subunit vaccines
    Ann Meyers
    Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Observatory 7925, South Africa
    BMC Biotechnol 8:53. 2008
    ..We partially purified a selected vaccine candidate and tested its stimulation of a humoral and cellular immune response in mice...
  83. ncbi Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways
    K McEvers
    California Department of Health Services, 850 Marina Bay Parkway, VRDL, Richmond, CA 94804, USA
    Vaccine 23:4128-35. 2005
    ..Additionally, we found that LFn--HIV is specific and sensitive in detecting HIV-specific CD4(+) and CD8(+) T cell responses in T cell assays, further broadening the value of this antigen delivery system as a useful immunologic tool...
  84. pmc HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype
    Simona Fiorentini
    Sections of Microbiology, General Pathology and Immunology, and Pathology, University of Brescia, I 25123 Brescia, Italy
    Proc Natl Acad Sci U S A 105:3867-72. 2008
    ..Based on these results, we propose a model where p17 induces immature circulating pDCs to home in lymph nodes devoid of their ability to serve as a link between innate and adaptative immune systems...
  85. ncbi Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice
    Michael A Egan
    Vaccine Discovery, Wyeth Vaccines Research, 401 N Middletown Rd, Bldg 180 216 10, Pearl River, NY 10965, USA
    Vaccine 24:4510-23. 2006
    ..These results have important implications for the design and development of an efficacious vaccine for the prevention of HIV-1 infection...
  86. ncbi A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells
    M I Bukrinsky
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha 68198 5120
    Nature 365:666-9. 1993
    ....
  87. ncbi Diversity of mosaic structures and common ancestry of human immunodeficiency virus type 1 BF intersubtype recombinant viruses from Argentina revealed by analysis of near full-length genome sequences
    Michael M Thomson
    Department of Viral Pathogenesis, Instituto de Salud Carlos III, Ctra Majadahonda Pozuelo, Km 2, 28220 Majadahonda, Madrid, Spain
    J Gen Virol 83:107-19. 2002
    ....
  88. pmc Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia
    F de Wolf
    Department of Virology, University of Amsterdam
    Br Med J (Clin Res Ed) 295:569-72. 1987
    ..9% in the HIV antigen positive group and 1.3% in the antigen negative group. HIV antibody seropositive men without symptoms but with persistent HIV antigenaemia are at increased risk of developing AIDS and AIDS related complex...
  89. ncbi HIV/AIDS. HLA leaves its footprints on HIV
    Andrew McMichael
    Weatherall Institute of Molecular Medicine, Oxford OX3 9DS, UK
    Science 296:1410-1. 2002
  90. pmc Immune selection for altered antigen processing leads to cytotoxic T lymphocyte escape in chronic HIV-1 infection
    Rika Draenert
    Howard Hughes Medical Institute, Charlestown, MA 02129, USA
    J Exp Med 199:905-15. 2004
    ..These results demonstrate that allele-associated sequence variation within the flanking region of CTL epitopes can alter antigen processing. Identifying such mutations is of major relevance in the construction of vaccine sequences...
  91. pmc HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor
    Maria A De Francesco
    Institute of Microbiology, University of Brescia Medical School, 25123 Brescia, Italy
    Proc Natl Acad Sci U S A 99:9972-7. 2002
    ..Our results define a role for p17 in HIV-1 pathogenesis and contribute to our understanding of the molecular mechanism of HIV-1 infection and the development of additional antiviral therapeutic strategies...
  92. ncbi Cytotoxic T lymphocytes recognize structurally diverse, clade-specific and cross-reactive peptides in human immunodeficiency virus type-1 gag through HLA-B53
    L Dorrell
    MRC Human Immunology Group, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, GB
    Eur J Immunol 31:1747-56. 2001
    ..These results demonstrate the value of combined immunological and structural analyses in defining novel CTL epitopes and have implications for HIV-1 vaccine design...
  93. ncbi Challenges and opportunities for development of an AIDS vaccine
    G J Nabel
    Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 3005, USA
    Nature 410:1002-7. 2001
    ....
  94. ncbi Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization
    J K Sandberg
    Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, 171 77, Sweden
    Virology 273:112-9. 2000
    ..Three Nef regions (16-35, 106-125, and 166-185) dominated the T helper cell proliferation. The implications of these results for the development of DNA-based vaccines against HIV is discussed...
  95. pmc Differential narrow focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic T-lymphocyte responses in infected African and caucasoid adults and children
    P J Goulder
    Partners AIDS Research Center, Massachusetts General Hospital, Charlestown, Massachusetts 02129, USA
    J Virol 74:5679-90. 2000
    ..The fine focusing of dominant CTL responses to these few regions of high immunogenicity is of significance to vaccine design...
  96. ncbi HEED, the product of the human homolog of the murine eed gene, binds to the matrix protein of HIV-1
    R Peytavi
    Laboratoire de Virologie Moléculaire and Pathogénèse Virale, CNRS UMR 5812, Faculte de Medecine, 2, Boulevard Henri IV, 34060 Montpellier, France
    J Biol Chem 274:1635-45. 1999
    ..This and the failure of HEED to bind to uncleaved GAG precursor suggested a role of HEED at the early stages of virus infection, rather than late in the virus life cycle...
  97. pmc Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1
    V Yusibov
    Biotechnology Foundation Laboratories, Thomas Jefferson University, 1020 Locust Street, Room 346 JAH, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 94:5784-8. 1997
    ..The plant-produced protein (virus particles) was purified and used for immunization of mice. Both antigens elicited specific virus-neutralizing antibodies in immunized mice...
  98. pmc Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism
    P Spearman
    Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 2581, USA
    J Virol 71:6582-92. 1997
    ....
  99. ncbi HIV-1 gag proteins: diverse functions in the virus life cycle
    E O Freed
    National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, 20892 0460, USA
    Virology 251:1-15. 1998
    ..This review briefly summarizes our current understanding of how HIV-1 Gag proteins function in the virus life cycle...
  100. pmc Human immunodeficiency virus-like particles activate multiple types of immune cells
    Gangadhara Sailaja
    Emory Vaccine Center and Department of Microbiology and Immunology, Rollins Research Center 3086, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA
    Virology 362:331-41. 2007
    ..VLPs containing FL were an effective form of antigen in activating immune cells via dendritic cells, and immunization with HIV VLPs containing FL resulted in enhanced T helper type 2-like immune responses...
  101. ncbi A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in Ad5 HIV Type 1 gag vaccinated human subjects
    Timothy W Tobery
    Department of Vaccines and Biologics Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA
    AIDS Res Hum Retroviruses 22:1081-90. 2006
    ....

Research Grants65

  1. Testing Primary HIV Infection in Seronegative Patients
    SPENCER BENNETT; Fiscal Year: 2005
    ..Abstract not provided ..
  2. Augmentation of DNA Vaccine-Elicited Immunity to HIV/SIV
    DAN BAROUCH; Fiscal Year: 2008
    ..The long-term objectives of these studies are to develop novel vaccine regimens that recruit APCs to the site of inoculation in animal models and to consider advancing the most promising strategies into clinical trials. ..
  3. Chimeric Adenovirus Vaccine Vectors for HIV/SIV
    DAN BAROUCH; Fiscal Year: 2005
    ..Within the two-year time frame of this award, sufficient data will be generated with candidate chimeric rAd vaccines to justify further vaccine/challenge studies in rhesus monkeys. ..
  4. Cytokine-Augmented DNA Vaccine-Elicited Immunity to HIV
    DAN BAROUCH; Fiscal Year: 2005
    ..Raphael Dolin, Dean for Clinical Programs, Harvard Medical School, will guide Dr. Barouch's development as an independent investigator. In addition, a committee of distinguished scientists will oversee his progress toward independence. ..
  5. Novel Adenovirus Vaccine Vectors for HIV/SIV
    Dan H Barouch; Fiscal Year: 2010
    ..abstract_text> ..
  6. A Genome-Derived, Epitope-Driven H. Pylori Vaccine
    Anne De Groot; Fiscal Year: 2006
    ..pylori disease as our correlate of efficacy. ..
  7. 2nd Annual Vaccine Renaissance Conference, RI
    Anne De Groot; Fiscal Year: 2006
    ..More than 80 participants attended that 1st conference from the[unreadable] New England region and beyond. ..
  8. Epitope Driven HIV Vaccine Development
    Anne De Groot; Fiscal Year: 2005
    ..The final product of this joint effort will be a set of plasmids to be combined in an epitope-driven, oligonucleotide-based DNA cocktail vaccine for HIV. ..
  9. A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE
    Anne De Groot; Fiscal Year: 2005
    ..abstract_text> ..
  10. Development of De-immunized Botulinum Neurotoxin Type A for Dystonia
    Anne De Groot; Fiscal Year: 2008
    ..Public Health Relatedness: Knowledge of the elements of botulinum neurotoxin type A that give rise to its immunogenicity will contribute to the development of improved dystonia therapy. [unreadable] [unreadable] [unreadable]..
  11. Novel Smallpox Vaccine Derived from VV/VAR Immunome
    Anne De Groot; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  12. Optimization of a Multivalent Tuberculosis Vaccine
    Anne De Groot; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  13. Polyvalent DNA Plus Protein HIV Vaccines
    Shan Lu; Fiscal Year: 2010
    ..This will allows us to effectively screen a large number of unique primary Env antigens to formulate the effective polyvalent HIV vaccines for the next phase of clinical testing. ..
  14. Apoptotic Mediators in HIV Associated Dementia
    Gwenn Garden; Fiscal Year: 2006
    ..How p53 may promote neurodegeneration through the modulation of caspase enzyme activity will also be studied. ..
  15. PERIODONTAL DISEASE:ROLE OF ABERRANT Ig GLYCOSYLATION
    Jiri Mestecky; Fiscal Year: 2006
    ..Results of these studies will generate information concerning previously unexplored inflammatory pathways that participate in the development of PD. ..
  16. Mucosal CTL Induction After HIV Exposure & Vaccination
    MARGARET MCELRATH; Fiscal Year: 2007
    ..abstract_text> ..
  17. HIV-1 and Host Cell Changes in Disease Progression
    James Mullins; Fiscal Year: 2007
    ..Data will be correlated with markers of disease progression, and correlates will be assessed for their ability to predict the critical events leading to disease, by targeted analysis of additional subjects. ..
  18. IMMUNOPATHOGENESIS OF ACUTE HIV-1 INFECTION
    Elizabeth Connick; Fiscal Year: 2007
    ..abstract_text> ..
  19. Molecular Mechanisms of HIV Disease Pathogenesis
    Kathleen L Collins; Fiscal Year: 2011
    ..This proposal is relevant to the mission of NIH in that it seeks to understand basic mechanisms of how HIV establishes a chronic infection. This work has the potential to have a significant impact on public health. ..
  20. Immunotherapeutic strategies for breast cancer
    YVONNE J PATERSON; Fiscal Year: 2010
    ....
  21. Enhancing Mucosal Cellular Imm Resp by Co-Delivery of Plasmid IL-15 w/DNA Vaccine
    Jean D Boyer; Fiscal Year: 2010
    ..AIM4 will investigate the peripheral and mucosal cellular immune responses in control and vaccinated animals following SIV challenge. ..
  22. To study cellular immune response in non-B clade HIV infection
    Huyen Cao; Fiscal Year: 2008
    ..3) To evaluate whether endemic co-infections may modulate of HIV-1 immununopathogenesis in Uganda, using Schistosoma mansoni as a model infection. ..
  23. COMPUTATIONAL TOOLS FOR RULE-BASED MODELING OF BIOCHEMICAL SYSTEMS
    WILLIAM HLAVACEK; Fiscal Year: 2009
    ..An important capability we wish to achieve is the ability to model a significant fraction of the known human signal-transduction systems. ..
  24. HIV Immunology Symposium-Uganda AIDS Conference
    Huyen Cao; Fiscal Year: 2008
    ..This forum is also intended to encourage young scientists from Africa and provide them with guidance and information to participate and contribute to the fight against AIDS. [unreadable] [unreadable] [unreadable] [unreadable]..
  25. Modulation of HIV-1 specific T cell function by TLR ligands
    Marcus Altfeld; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  26. Molecular basis for HIV therapy-linked osteopenia
    Jeffrey Laurence; Fiscal Year: 2008
    ....
  27. Simple Test for Identifying Recent HIV Infection
    Niel Constantine; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  28. HIV VACCINES TRIAL UNITS
    MARGARET MCELRATH; Fiscal Year: 2006
    ..Coordinated efforts will be required among academic and governmental institutions, industry, and the international communities. We are committed to these activities as we seek a long-term solution to the HIV-1 epidemic. ..
  29. Second Generation Rabies Vaccines
    James McGettigan; Fiscal Year: 2007
    ..The development of treatment that relies on only one to two doses of vaccine instead of six inoculations will greatly enhance the effectiveness of rabies virus prevention. [unreadable] [unreadable] [unreadable]..
  30. Olympus FV-1000 Confocal Microscope
    Gwenn Garden; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  31. Protective Immune Responses in HIV-1 Exposed Infants
    Carey Farquhar; Fiscal Year: 2006
    ..Kreiss and John, will prepare her for the complex data analysis required by this study and contribute substantially to the development of her career as an independent clinical investigator. ..
  32. Familial IgA Nephropathy: Genetic and Metabolic Studies
    Jiri Mestecky; Fiscal Year: 2006
    ..abstract_text> ..
  33. Peptide Vaccine for Experimental Autoimmune Myocarditis
    Daniel Zimmerman; Fiscal Year: 2003
    ..The effects of J-My-1 administration on the presence and frequency of this cell type will be evaluated. Our goal is to demonstrate that the severity of EAM can be reduced by J-My-1 administration in animals with EAM. ..
  34. derG Immunostimulant Prevention/Treatment of HSV Disease
    Daniel Zimmerman; Fiscal Year: 2003
    ..An integral part of the phase II program will be to further elucidate the target cells and mechanism of action of derG. ..
  35. CD8+TCell Antiretroviral Mechanisms in Lymphoid Tissue
    Elizabeth Connick; Fiscal Year: 2003
    ..These studies could provide important insight into the immunopathogenesis of HIV-1 infection and suggest alternative targets for immune therapies. ..
  36. Interactions Between Recombinant Yeast and Blood DCs
    Cara Wilson; Fiscal Year: 2004
    ....
  37. ANTIVIRAL THERAPY AND COMPARTMENTS OF HIV IN VIVO
    James Mullins; Fiscal Year: 2002
    ....
  38. Conference on HIV-1 Protection & Control by Vaccination
    MARGARET MCELRATH; Fiscal Year: 2002
    ..The symposium will educate and engage those persons in training to pursue areas of HIV-1 vaccine research and will provide renewed commitment for those investigators already dedicated to vaccine development. ..
  39. COALESCENT METHODS FOR MEASURABLY EVOLVING POPULATIONS
    James Mullins; Fiscal Year: 2001
    ..Develop a coalescent-likelihood method which uses serial samples to estimate piecewise exponential changes in effective population size. ..
  40. BIOLOGY OF PEDIATRIC HEPATITIS C INFECTION
    William Borkowsky; Fiscal Year: 2001
    ..The influence of both maternal and child alleles on transmission will be assessed. The correlation of immune responses measured in AIM 3 and the clinical outcome of HCV infection with HLA alleles in the child will be studied. ..
  41. Parasitic Infection Alters Quality of Immune Response
    Jean Boyer; Fiscal Year: 2003
    ..This proposal represents the initiation of a new and important area of research. ..
  42. ABI PRISM 7700 SEQUENCE DETECTION SYSTEM
    William Borkowsky; Fiscal Year: 2001
    ..The principal investigator will be responsible for helping design primers and probes for the instrument as well as insure that the assay and those who manage it undergo appropriate quality control procedures. ..
  43. New World Oncogenic Lymphocryptoviruses
    Frederick Wang; Fiscal Year: 2005
    ..Specific aim #3. Study the disease association, epidemiology, and evolution of New World LCV. Specific aim #4. Develop an experimental Ca1HV-3 animal model to study the pathogenesis of persistent infection and virus-induced oncogenesis. ..
  44. Immunology International Conference "Correlates of Disease Progression in Africa"
    Huyen Cao; Fiscal Year: 2006
    ..The possibility of[unreadable] creating a network to promote immunology training and research among investigators[unreadable] from this region will also be on the agenda. ..
  45. Multi-gene plague vaccine with expanded protection
    Shan Lu; Fiscal Year: 2004
    ..This project will employ the most advanced DNA immunization technology in combination with small-scale protein production to quickly develop potential subunit-based plague vaccine products. ..
  46. THE ENDOTHELIAL CELL IN PATHOGENESIS OF TTP
    Jeffrey Laurence; Fiscal Year: 2004
    ..The model presented could also enable exploration of new therapeutic modalities for TTP, based upon modulation of specific apoptotic pathways. ..
  47. Modeling, Estimation and Control in HIV Dynamics
    H Banks; Fiscal Year: 2005
    ....
  48. Protective cellular immune responses in HIV-1 discordant couples
    Carey Farquhar; Fiscal Year: 2010
    ....
  49. New approach to T cell study for Vaccine in Uganda
    Huyen Cao; Fiscal Year: 2005
    ..Production of LFn-HIV containing HIV antigens up to 500 amino acids is technically simple, relatively inexpensive, and is, therefore, an attractive ..
  50. PEDIATRIC AIDS CLINICAL TRIALS UNIT
    William Borkowsky; Fiscal Year: 2002
    ..This effort will also be helped by established links to previously funded community resources, our community advisory board, and by our own local General Clinical Research Center. ..
  51. Cellular Immune Response to non-B Clade HIV Infection
    Huyen Cao; Fiscal Year: 2007
    ..abstract_text> ..
  52. OCCURRENCE AND OUTCOME OF DUAL HIV-1 INFECTION
    James Mullins; Fiscal Year: 2004
    ....
  53. NCRR FACSAria Cell Sorter
    Barton Haynes; Fiscal Year: 2004
    ..Advisory committees, institutional support, financial support for continued maintenance, and management plans are in place to insure that the instrument will be fully and appropriately utilized. ..
  54. Augmenting innate and vaccine immune response with der-G
    Daniel Zimmerman; Fiscal Year: 2003
    ..In these studies we will follow survival and ovarian viral titers after intranasal challenge with VV. The studies will also analyze the mechanism of action to identify immune surrogates for use in clinical studies. ..
  55. System-wide Study of Transcriptional Control of Metabolism
    WILLIAM HLAVACEK; Fiscal Year: 2008
    ..anthracis, this research would also represent an important test bed for a subsequent study of metabolic diseases in higher animals, including humans. [unreadable] [unreadable] [unreadable]..
  56. IMMUNOGENICITY OF HIV PROTEINS DELIVERED BY LIVE VECTOR
    Yvonne Paterson; Fiscal Year: 2004
    ..These studies will start in year 2 of the proposal. The hypothesis of this aim is that the attenuated strains will as effective as wild-type Listeria in delivering SHIV antigens to the immune system. ..
  57. CASPASE ENZYMES & APOPTOSIS IN HIV INDUCED NEURAL INJURY
    Gwenn Garden; Fiscal Year: 2003
    ..abstract_text> ..
  58. Bacterial vector vaccine: Her-2/neu expressing tumors
    Yvonne Paterson; Fiscal Year: 2005
    ..This work will demonstrate the utility of the L. monocytogenes-based vaccines, thus setting the stage for further development of a breast cancer therapeutic that can be used in humans. ..
  59. Effect of Schistosoma Co-infection on HIV Immune Responses
    Huyen Cao; Fiscal Year: 2007
    ..mansoni infection dysregulates cellular immune responses by enhancing the activity of IL-10-producing T cells. S. mansoni co-infection will therefore be examined in the context of being an experimental immune modulator. ..
  60. MVA/HIV-48: Potential Dual Vaccine for HIV and Smallpox
    Rama Rao Amara; Fiscal Year: 2003
    ..The project will be a collaborative undertaking between researchers at the CDC, the NIAID, and the NIAID HIV Vaccine Trial Network (HVTN ). The focus of this application is the quantification and phenotyping of responding T cells. ..